Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Entrada Therapeutics Inc TRDA

Healthcare Biotechnology
Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company’s Endosomal Escape Vehicle (EEV™)-therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a... see more

Current News (NDAQ:TRDA)

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 7 days ago

Entrada Therapeutics Reports Third Quarter 2025 Financial Results

GlobeNewswire November 6, 2025

Entrada Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire October 28, 2025

Entrada Therapeutics Announces Recipients of Third Annual DREAMS Grant Program

GlobeNewswire September 5, 2025

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire September 2, 2025

Entrada Therapeutics Reports Second Quarter 2025 Financial Results

GlobeNewswire August 6, 2025

Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

GlobeNewswire June 3, 2025

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire June 2, 2025

Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

GlobeNewswire May 28, 2025
View More News ››

Opinion & Analysis (NDAQ:TRDA)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:TRDA)

Entrada Therapeutics (TRDA): Pioneering a New Class of Intra

Looks like TRDA is making some serious moves in the rare disease space. Their EEV platform is legit - just bagged a massive $223.7M...
MikeTester - January 23, 2025
View more Bullboard ››

Birchtech Corp.

Birchtech Corp.

Birchtech Corp., an environmental services and technology company, engages in developing and delivering solutions to the ...
View More »